FDA panel backs six experimental peptides, but compounding still barred

The advisory committee that advises the Food and Drug Administration voted in late July to endorse the production of six of the seven peptide therapies under review, but the recommendation does not yet allow compounding pharmacies to make them.

Agency scientists warned that none of the seven candidates have completed the large‑scale human trials required for full drug approval. The split vote – in favor of all but one peptide – leaves a legal gray area: the substances remain illegal for compounding until the FDA’s staff and leadership either place them on a “Category One” list or pursue a different pathway.

What the panel decided

• Late July – A marathon hearing convened the FDA’s advisory committee.
• Committee vote – Six of the seven peptides received a positive recommendation; one was rejected.
• Current status – Compounding pharmacies are still prohibited from producing any of the seven peptides.

Dr. Jessica Duncan, chief medical officer of IVIM Health, told patients that “they are now even more curious” and that the timeline for any change remains uncertain.

Regulatory paths on the table

Lawyer Jesse Dresser of the firm Frier Levitt, who represents compounding pharmacies, said the FDA will likely pursue a faster route than the traditional rulemaking process that can stretch over many months. He told Npr that “it would actually surprise me if this followed the traditional pathway of formal rulemaking,” and added that any options to accelerate the decision will be explored.

One possibility, outlined by former FDA official Ilisa Bernstein, is to place the endorsed peptides on the “Category One” list. That would grant compounding pharmacies interim authority to produce the drugs while a longer‑term rulemaking proceeds. Bernstein cautioned that “the agency needs to follow the data,” emphasizing the need for safety safeguards before a broad market rollout.

Health Secretary Robert F. Kennedy Jr. Has publicly urged the agency to make the peptides available, arguing that the unregulated gray market poses a public‑health risk. Dresser noted that the Secretary could invoke that same concern to fast‑track the compounds onto the Category One list, a move that “would almost certainly result in a legal challenge,” according to him.

Conversely, some experts warn the FDA could reject the panel’s recommendation altogether. Attorney Abha Kundi of Aaron Fox Schiff said the agency might decide against changing the status of the peptides, which would likely trigger lawsuits from the compounding industry. She also observed that the agency appears “very attuned” to the real‑world landscape of unregulated peptide use.

Industry reaction

Scott Brunner, head of the Alliance for Pharmacy Compounding, predicts a chaotic rollout if the FDA grants compounding permission. “It might take two months, it might take nine months, it depends on the substance,” he said, noting that pharmacies will need to secure active ingredients before they can begin compounding.

Dr. Haleem Mohammed, chief medical officer of Gameday Men’s Health and a panelist who voted in favor, warned that the current gray market “is a lot seedier than what people think.” He argued that a regulated pathway would move the products out of unvetted “research‑purpose” channels and into a safer, prescription‑based system.

Endocrinologist Dr. Harmeet Narula of Banner Health echoed concerns about the gap between commercial hype and clinical evidence, stating that the panel’s vote “does not mean these drugs are FDA approved.” He emphasized that most traditional physicians remain wary of prescribing peptides without robust guidelines.

What patients can expect now

Even if the FDA clears the peptides for compounding, they will still require a prescription and will likely be dispensed only by specialized compounding pharmacies rather than retail chains. Direct‑to‑consumer telehealth platforms, med spas and longevity clinics are already marketing peptide therapies, but the lack of evidence‑based guidelines means that prescribing practices will vary widely.

Professional societies have begun offering peptide‑focused training and certification, yet no major medical association has issued standardized usage recommendations. This regulatory vacuum fuels the “commercial enthusiasm is outpacing clinical science” sentiment voiced by Dr. Narula.

What to watch next

• Potential Category One listing – If granted, compounding pharmacies could start producing the six endorsed peptides while rulemaking continues.
• Legal challenges – Industry groups may file lawsuits if the FDA rejects the panel’s advice or delays action.